Diphtheria

Back

Background

C diphtheria is responsible for both endemic and epidemic diseases, and it was first described in the 5th century BC by Hippocrates. Diphtheria manifests as either an upper respiratory tract or cutaneous infection and is caused by the aerobic gram-positive bacteria, Corynebacterium diphtheria. The infection usually occurs in the spring or winter months. It is communicable for 2-6 weeks without antibiotic treatment.[1, 2] People who are most susceptible to infection are those who are not completely immunized or have low antitoxin antibody levels and have been exposed to a carrier or diseased individual. A carrier is someone whose cultures are positive for the diphtheria species but does not exhibit signs and symptoms. Studies show that as the number of asymptomatic carriers decrease, the number of diphtheria cases consequently decline.[1, 3]

C diphtheria is a nonencapsulated, nonmotile, gram-positive bacillus; this is shown in the image below. Pathogenic strains can result in severe localized upper respiratory infection, localized cutaneous infections, and rarely systemic infection.



View Image

Photomicrograph depicts a number of gram-positive Corynebacterium diphtheriae bacteria, which had been stained using the methylene blue technique. The....

Exotoxins are associated with both invasive localized and systemic forms of this disease; however, case reports of invasive disease in absence of the exotoxin release have been documented.[1] Exotoxins are encoded in viral bacteriophages, which are transmitted from bacteria to bacteria. The 3 isolated strains of C diphtheria include gravis, intermedius, and mitis. Intermedius is thought to be responsible for systemic elaboration of the disease, as it is most often associated with the exotoxin. However, all 3 strains are capable of producing toxins.[1, 2]

Corynebacterium ulcerans is a relatively rare species, which more frequently causes cutaneous diphtheria; however, this species may rarely cause respiratory symptoms. Severity of disease is dependent on exotoxin production. C ulcerans has also been linked to zoonotic transmission to humans and has been most frequently seen in agricultural communities associated with livestock.[4, 5]

The use of diphtheria and tetanus toxoids and acellular pertussis (DTaP) in the United States has greatly decreased the incidence of diphtheria. Although childhood DTaP coverage exceeds 80%, acquired immunity wanes over time, requiring a booster to preserve immunity. Although vaccination is not guaranteed to prevent diphtheria, vaccinated persons who go on to develop diphtheria have been reported as having milder and less fatal infections.[6]

Pathophysiology

Overcrowding, poor health, substandard living conditions, incomplete immunization, and immunocompromised states facilitate susceptibility to diphtheria and are risk factors associated with transmission of this disease.[7] Human carriers are the main reservoir of infection; however, case reports have linked the disease to livestock.[5, 4] Infected patients and asymptomatic carriers can transmit C diphtheria via respiratory droplets, nasopharyngeal secretions, and rarely fomites.[1, 2] In the case of cutaneous disease, contact with wound exudates may result in the transmission of the disease to the skin as well the respiratory tract.[4]

Immunity from exposure or vaccination wanes over time. Inadequate boosting of previously vaccinated individuals may result in increased risk of acquiring the disease from a carrier, even if adequately immunized previously. Additionally, since the advent of widespread vaccination, cases of nontoxigenic strains causing invasive disease have increased.[8]

C diphtheria adheres to mucosal epithelial cells where the exotoxin, released by endosomes, causes a localized inflammatory reaction followed by tissue destruction and necrosis. The toxin is made of two joined proteins.[2] The B fragment binds to a receptor on the surface of the susceptible host cell, which proteolytically cleaves the membrane lipid layer enabling segment A to enter.[1] Molecularly, it is suggested that the cellular susceptibility is also due to diphthamide modification, dependent on human leukocyte antigen (HLA) types predisposing to more severe infection. The diphthamide molecule is present in all eukaryotic organisms and is located on a histidine residue of the translation elongation factor 2 (eEF2). eEF2 is responsible for the modification of this histidine residue and is the target for the diphtheria toxin (DT).

Fragment A inhibits an amino acid transfer from RNA translocase to the ribosomal amino acid chain, thus inhibiting protein synthesis is required for normal host cell functioning.[1] DT causes a catalytic transfer of NAD to diphthamide, which inactivates the elongation factor, resulting in the inactivation eEF2, which results in protein synthesis blockage and subsequent cell death.[9, 2]

Local tissue destruction enables the toxin to be carried lymphatically and hematologically to other parts of the body. Elaboration of the diphtheria toxin may affect distant organs such as the myocardium, kidneys, and nervous system. Nontoxigenic strains tend to produce less severe infections; however, since widespread vaccination, case reports of nontoxigenic strains of C diphtheria causing invasive disease have been documented.[1]

Epidemiology

Frequency

United States

Since the introduction and widespread use of diphtheria toxoid in the 1920s, respiratory diphtheria has been well controlled, with an incidence of approximately 1000 cases reported annually. Before vaccination, at least 200,000 cases occurred annually in the United States.[10]

Diphtheria remained endemic in some states through the 1970s, with reported incidence rates of greater than 1.0 per million population in Alaska, Arizona, Montana, New Mexico, South Dakota, and Washington.[1] Most of these infections were attributed to incomplete vaccination.

In the United States, diphtheria currently occurs sporadically, mostly among the Native American population, homeless people, lower socioeconomic groups, and alcoholics.[7] Immigrants and travelers from regions with ongoing epidemics are also at risk.[7]  The most recent data from the CDC show that, between 1996 and 2016, only 13 cases were reported.[6]

International

According to the World Health Organization (WHO), diphtheria epidemics remain a health threat in developing nations.[2] The largest epidemic recorded since widespread implementation of vaccine programs was in 1990-1995, when a diphtheria epidemic emerged in the Russian Federation, rapidly spreading to involve all Newly Independent States (NIS) and Baltic States. This epidemic caused more than 157,000 cases and 5000 deaths according to WHO reports.[11, 12] Disproportionately high rates of death were observed in individuals older than 40 years, and 5,000 deaths were reported. This epidemic accounted for 80% of cases reported worldwide during this time period.[13]

From 1993-2003, a decade long epidemic in Latvia resulted in 1359 reported cases of diphtheria with 101 deaths. The incidence fell from 3.9 cases per 100,000 cases in 2001 to 1.12 cases per 100,000 population in 2003. Most cases were registered in unvaccinated adults.

From 1995-2002, 17 cases of cutaneous diphtheria due to toxigenic strains were reported in the United Kingdom.[13]

Overall rates of infection have decreased in Europe from 2000 to 2009, according to the Diphtheria Surveillance Network. This has been attributed to improved vaccination rates creating herd immunity. However, issues with vaccinations still occur, especially in eastern European countries and Russia, and are thought to contribute to the ongoing outbreaks.[14]

Many case reports in the literature describe epidemics in sub-Saharan Africa, France, India, and the United States.[15, 16]

Mortality/Morbidity

Before the introduction of vaccine in the 1920s, the incidence of respiratory disease was 100-200 cases per 100,000 population in the United States and has decreased to approximately 0.001 cases per 100,000 population.[10, 1]

The most widely quoted diphtheria mortality rate is 5-10%. It may reach higher than 20% in children younger than 5 years and adults older than 40 years. Immunization patterns have the most influence on mortality patterns. Mortality rates have not changed significantly over the past few decades. Most deaths occur on days 3-4 secondary to asphyxia with a pharyngeal membrane or due to myocarditis. Mortality rates of 30-40% have been reported for bacteremic disease.[10]

Race

No racial predilection for diphtheria has been reported.

Sex

No significant differences exist between the incidence of diphtheria in males and females. In certain regions of the world, however, women may have lower immunization rates than males. Female infants and young children account for the majority of deaths in endemic regions.

Age

Historically, diphtheria has been primarily a disease of childhood, affecting populations younger than 12 years. Infants become susceptible to the disease at age 6-12 months after their transplacentally derived immunity wanes.[17] Since the advent of diphtheria vaccination, cases of pediatric disease have declined dramatically. Recently, however, diphtheria has shifted into the adolescent and adult population, most notably in ages 40 and older accounting for most new cases.[12] This is primarily due to incomplete immunization status, including never being immunized, inefficient vaccine or response to vaccination, and not receiving a booster after previous vaccination. According to immunologic studies, one must have an antitoxin level of greater 0.1 IU/mL for adequate immunity.[18] Additionally, adolescents and adults may exhibit an atypical presentation of the disease, thus potentially obscuring the diagnosis.[8]

Immunization schedules have recently changed requiring a toxoid booster at age 11-12 and every 10 years thereafter. The toxoid booster, without tetanus, is approved for pregnant women if their antitoxin titers are less than 0.1 IU/mL.[18]

History

Onset of symptoms of respiratory diphtheria typically follows an incubation period of 2-5 days (range, 1-10 d).[1, 10] Symptoms initially are general and nonspecific, often resembling a typical viral upper respiratory infection (URI). Respiratory involvement typically begins with sore throat and mild pharyngeal inflammation. Development of a localized or coalescing pseudomembrane can occur in any portion of the respiratory tract. The pseudomembrane is characterized by the formation of a dense, gray debris layer composed of a mixture of dead cells, fibrin, RBCs, WBCs, and organisms; the pseudomembrane is shown in the image below.



View Image

The characteristic thick membrane of diphtheria infection in the posterior pharynx.

Removal of the membrane reveals a bleeding, edematous mucosa. The distribution of the membrane varies from local (eg, tonsillar, pharyngeal) to widely covering the entire tracheobronchial tree. The membrane is intensely infectious, and droplet and contact precautions must be followed when examining or caring for infected patients. A combination of cervical adenopathy and swollen mucosa imparts a "bull's neck" appearance to many of the infected patients; this is shown in the image below. The most frequent cause of death is airway obstruction or suffocation following aspiration of the pseudomembrane.[17]



View Image

Cervical edema and cervical lymphadenopathy from diphtheria infection produce a bull's neck appearance in this child. Source: Public Domain www.immuni....

Cutaneous diphtheria is a disease characterized by indolent, nonhealing ulcers covered with a gray membrane. The ulcers are often co-infected with Staphylococcus aureus and group A streptococci. This form of the disease is seen with increasing frequency in poor inner-city dwellers and alcoholics. The lesions of cutaneous diphtheria are infectious, and bacteria from cutaneous lesions have been found to cause pharyngeal infections and thus serve as a reservoir for infection.

Patients with diphtheria may present with the following complaints:

Respiratory diphtheria may quickly progress to respiratory failure due to airway obstruction or aspiration of pseudomembrane into the tracheobronchial tree.

Cutaneous diphtheria often develops at a site of previous trauma or a primary dermatologic disease. It follows an indolent course, typically lasting weeks to months. Occasionally, it may cause respiratory diphtheria.[17]

Physical

General: Patient has a low-grade fever but is toxic in appearance, and also may have a swollen neck.

Pharyngeal diphtheria:

Cardiac toxicity typically occurs after 1-2 weeks of illness following improvement in the pharyngeal phase of the disease. It may manifest as follows:

Neurologic toxicity is proportional to the severity of the pharyngeal infection. Most patients with severe disease develop neuropathy. Deficits include the following:

Causes

The following factors may predispose to diphtheria infection:

Laboratory Studies

To establish the diagnosis of C diphtheriae, it is vital to both isolate C diphtheriae in culture media and to identify the presence of toxin production.[2]

Bacteriologic testing

Gram stain shows club-shaped, nonencapsulated, nonmotile bacilli found in clusters.

Immunofluorescent staining of 4-hour cultures or methylene blue–stained specimen may sometimes allow for a speedy identification.

Cultures

Inoculation of tellurite or Loeffler media with swabs taken from the nose, pseudomembrane, tonsillar crypts, any ulcerations, or discolorations. Identification is accomplished through observation of colony morphology, microscopic appearance, and fermentation reactions. Any diphtheria bacilli isolated must be tested for toxin production.

Obtain throat and pharyngeal swabs from all close contacts.[10]

Toxigenicity

Toxigenicity testing is aimed to determine the presence of toxin production.

Elek test detects the development of an immunoprecipitin band on a filter paper impregnated with antitoxin and then is laid over an agar culture of the organism being tested.[11]

Polymerase chain reaction (PCR) assays for detection of DNA sequence encoding the A subunit of tox+ strain are both rapid and sensitive.

Once diphtheria infection has been established, the Centers for Disease Control and Prevention (CDC) should be contacted, and further testing may be requested.

Other laboratory studies

CBC may show moderate leukocytosis.

Urinalysis (UA) may demonstrate transient proteinuria.

Serum antibodies to diphtheria toxin prior to administration of antitoxin: Low levels cannot exclude the possibility of the disease; high levels may protect against severe illness (concentrations of 0.1 to 0.01 IU are thought to confer protection).[10]

Serum troponin I levels seem to correlate with the severity of myocarditis.[23]

Imaging Studies

Chest radiograph and soft tissue neck radiography/CT or ultrasonography may show prevertebral soft tissue swelling, enlarged epiglottis, and narrowing of the subglottic region.

Echocardiography may demonstrate valvular vegetations; however, this systemic manifestation of diphtheria is rare.[23, 24]

Other Tests

ECG may show ST-T wave changes, variable heart block, and dysrhythmia.

Procedures

The following procedures may be necessary:

Prehospital Care

Careful assessment of airway patency and cardiovascular stability. Patients should be transported to the nearest hospital.

Emergency Department Care

Treatment of diphtheria should be initiated even before confirmatory tests are completed due to the high potential for mortality and morbidity.

Isolate all cases promptly and use universal and droplet precautions to limit the number of possible contacts.

Secure definite airway for patients with impending respiratory compromise or the presence of laryngeal membrane. Early airway management allows access for mechanical removal of tracheobronchial membranes and prevents the risk of sudden asphyxia through aspiration. Consider involving ENT or operating room personnel for intubation and securing of airway if there is suspicion for loss of the airway or respiratory failure.

Maintain close monitoring of cardiac activity for early detection of rhythm abnormalities. Initiate electrical pacing for clinically significant conduction disturbance and provide pharmacologic intervention for arrhythmias or for heart failure.

Provide 2 large-bore IVs for patients with a toxic appearance; provide invasive monitoring and aggressive resuscitation for patients with septicemia.

Initiate prompt antibiotic coverage (erythromycin or penicillin) for eradication of organisms, thus limiting the amount of toxin production. Antibiotics hasten recovery and prevent the spread of the disease to other individuals.

Neutralize the toxin as soon as diphtheria is suspected. Diphtheria antitoxin is a horse-derived hyperimmune antiserum that neutralizes circulating toxin prior to its entry into the cells. It prevents the progression of symptoms. The dose and route of administration (IV vs IM) are dependent on the severity of the disease. This antitoxin must be obtained directly from the Centers for Disease Control and Prevention (CDC) through an Investigational New Drug (IND) protocol. The patient must be tested for sensitivity to the antitoxin before it is given. Antitoxin is only available in the United States. For more information regarding acquisition, see the CDC website for diphtheria antitoxin.

Diphtheria disease does not confer immunity; thus, initiation or completion of immunization with diphtheria toxoid is necessary.

Obtain throat and nasal swabs from persons in close contact with the suspected diphtheria victim; administer age-appropriate diphtheria booster.

Initiate antibiotic therapy with erythromycin or penicillin for chemoprophylaxis in a patient with suspected exposure. Throat cultures should be repeated in 2 weeks after treatment.

Consultations

The following consultations may be necessary:

Prevention

The widespread use of the diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine in childhood has significantly decreased the incidence of diphtheria. However, childhood immunity wanes, requiring an updated booster vaccine. The CDC recommends either DTaP, Tdap, or DT at least every 10 years to maintain immunity.[6]

Medication Summary

Patients with active disease as well as all close contacts should be treated with antibiotics. Treatment is most effective in the early stages of disease and decreases the transmissibility and improves the course of diphtheria. Additionally, close contacts, such as family members, household contacts, and potential carriers, must receive chemoprophylaxis regardless of immunization status or age. This entails treatment with erythromycin or penicillin for 14 days and post treatment cultures to confirm eradication.[3]

The CDC has approved macrolides such as erythromycin as first-line agents for patients older than 6 months of age. However, macrolide therapy has been associated with an increase in pyloric stenosis in children younger than 6 months, especially treatment with erythromycin. Intramuscular penicillin is recommended for patients who will be noncompliant or intolerant to an erythromycin course.

The horse serum antitoxin is given to anyone suspected to have diphtheria and can be administered without confirmation from cultures, as it is most efficacious early during the course of the disease.

Diphtheria antitoxin can be obtained only from the CDC. For more information regarding acquisition, see the CDC website for diphtheria antitoxin.

Diphtheria antitoxin

Clinical Context:  Neutralizes toxin before it enters cells. Dose given depends on site of infection and length of time patient is symptomatic. In United States, diphtheria antitoxin (DAT) is available from the CDC. Contact a diphtheria duty officer through CDC’s Emergency Operations Center at 770-488-7100. Report all suspected cases of diphtheria to local and state health departments.

Class Summary

Diphtheria antitoxin was first used in the United States in 1891, derived from a horse serum, it neutralizes unbound exotoxin. It is to be administered as soon as diphtheria suspected. It can only be obtained from the CDC and is not available internationally. Administer immunization toxoid booster, as the antitoxin does not influence immunity.

Erythromycin (E-Mycin, Ery-Tab)

Clinical Context:  Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections.

Age, weight, and severity of infection determine proper dosage in children. When bid dosing is desired, one half the total daily dose may be taken q12h. Double the dose for more severe infections.

Has the added advantage of being a good anti-inflammatory agent by inhibiting migration of polymorphonuclear leukocytes.

Class Summary

Erythromycin and penicillin are both recommended for the treatment of diphtheria. Some studies suggest that erythromycin may be better at eradication of the carrier state. Penicillin is recommended in household contacts who may not comply with the duration of erythromycin treatment. An increased incidence of pyloric stenosis is associated with administration of erythromycin to infants younger than 6 months. It is believed that azithromycin may be a better macrolide treatment in this population, though there are a few case reports describing pyloric stenosis in infants treated with azithromycin for pertussis infections.

The treatment of endocarditis requires the addition of an aminoglycoside.

Penicillin G benzathine (Bicillin L-A, Permapen)

Clinical Context:  Interferes with synthesis of cell wall mucopeptides during active multiplication, which results in bactericidal activity. Effective treatment for systemic diphtheria.

Class Summary

Penicillin may be used for treatment, prophylaxis, and eradication of diphtheria in carriers. However, resistant strains and transmission from penicillin-treated carriers has been reported.

Further Outpatient Care

Complete age-appropriate immunization schedule.

Treat all household and other close contacts with antibiotics as mentioned above. All suspected and confirmed carriers should be treated with erythromycin or penicillin for 14 days.

Follow-up pharyngeal cultures must be obtained post treatment, confirming eradication of the bacterium.[3]

Further Inpatient Care

Provide supportive care, continuation of antibiotic treatment, and antipyretics for fever.

Closely observe for development of primary or secondary bacterial pneumonia.

Perform serial ECGs to detect cardiac abnormalities.

Provide physical therapy for patients with neurologic dysfunction.

Patients with endocarditis may require valve replacement, especially with previous prosthetic valves. However, some evidence suggests that antibiotic therapy with a beta-lactam with or without an aminoglycoside may be adequate in treating endocarditis with either a native or prosthetic valve.[20]

Respiratory isolation may be indicated.

Monitor for serum sickness or hypersensitivity reactions in patients treated with DAT.

Inpatient & Outpatient Medications

The following medications may be necessary:

Transfer

Intensive care unit admission is recommended for patients with impending respiratory compromise.

Isolation may be indicated.

Deterrence/Prevention

The Global Pertussis Initiative formed in 2001 is the task force working towards global immunizations and disease prevention in infants, adolescents, and adults for diphtheria, pertussis, and tetanus.

The 4 forms of the diphtheria toxoid are as follows: DTaP, Tdap, DT, and Td. The childhood vaccination is called DTaP. Adult vaccination form is Tdap. These toxoid vaccinations are combined with acellular pertussis and tetanus vaccine.[25]

DTap is given at 2 months, 4 months, 6 months, 15-18 months, and 4-6 years. The uppercase D denotes the full strength of tetanus toxoid (7-8 Lf units).[26]

DT does not contain pertussis and is given to children who have had previous adverse reactions to the acellular pertussis incorporated vaccine.

Td is a vaccine for adolescents and adults given as a booster every 10 years or when an exposure has occurred. The lowercase d denotes reduced strength diphtheria toxoid (2.0-2.5 Lf units). It is given to those older than 7 years.[27]

Tdap is recommended for adolescents aged 11-12 years or in place of one Td booster in older adolescents and adults aged 19 years and older.[28] In 2012, the CDC recommended patients 65 years and older receive Tdap if they have not received it previously. Boostrix is Tdap approved for adolescents aged 10 years and older, and Adacel is Tdap approved for those aged 11-64 years. For those 65 and older, the CDC recommends Boostrix. However, either Boostrix or Adacel may be used depending on availability.

The CDC also recommends that pregnant patients greater than 20 weeks’ gestation be given Tdap during pregnancy or shortly after delivery.[29] CDC’s Advisory Committee for Immunization Practices recently recommended that pregnant patients greater than 20 weeks’ gestation receive Tdap regardless of previous Tdap history.[30] This allows maternal antibodies to pass on to the fetus, giving protection for the few months of life.

These immunization schedules have been modified due to trends of pertussis increasing in the adolescent and adult populations. Therefore, Tdap Boostrix, and Adacel are now recommended in the immunization schedule for prevention of endemics associated with pertussis and diphtheria.[31, 29, 28]

Contact/respiratory isolation is indicated for prevention and deterrence of spreading the infection.

Complications

See the list below:

Prognosis

Cardiac involvement is associated with a very a poor prognosis, particularly AV and left bundle-branch blocks (mortality rate 60-90%).

Bacteremic disease carries a mortality rate of 30-40%.

High mortality rate is seen with invasive disease.

High mortality rates are seen in individuals younger than 5 years and in those older than 40 years.

Patient Education

Widespread awareness of the need for universal immunization is indicated.

Stress the importance of seeking medical attention in all cases of contact with suspected diphtheria cases.

What is diphtheria?What factors contribute to susceptibility to diphtheria?What is the pathophysiology of diphtheria?How common is diphtheria in the US?What is the global incidence of diphtheria?What is the mortality rate of diphtheria?Does diphtheria have a racial predilection?Is diphtheria more common in males or females?Which age group is most commonly affected by diphtheria?What are the signs and symptoms of respiratory diphtheria?How is cutaneous diphtheria characterized?What are common presenting complaints in patients with diphtheria?What is the clinical course of respiratory diphtheria?What is the clinical course of cutaneous diphtheria?What are the general clinical findings in diphtheria?What are the clinical findings in pharyngeal diphtheria?How is cardiac toxicity characterized in diphtheria?How does neurologic toxicity manifest in diphtheria?What factors predispose individuals to diphtheria infection?What are the differential diagnoses for Diphtheria?Which lab studies definitively diagnose diphtheria?How is diphtheria characterized on Gram stain?How is diphtheria characterized in cultures?What is the role of toxigenicity testing in the workup of diphtheria?What nonspecific lab findings are seen in cases of diphtheria?What is the role of imaging studies in the workup of diphtheria?What is the role of ECG in the workup of diphtheria?Which procedures may be indicated during the workup of diphtheria?What is the prehospital care for diphtheria?When should treatment of diphtheria be initiated?Why is it important to secure an airway in patients with diphtheria?What is the role of cardiac monitoring in the treatment of diphtheria?How is diphtheria treated in patients with a toxic appearance?Which specialist consultations may be indicated in the treatment of diphtheria?How effective is diphtheria vaccination, and how often are booster vaccines recommended?Which medications are used in the treatment of diphtheria?Which medications in the drug class Antibiotic, Penicillin are used in the treatment of Diphtheria?Which medications in the drug class Macrolides are used in the treatment of Diphtheria?Which medications in the drug class Antitoxins are used in the treatment of Diphtheria?What follow-up monitoring is indicated in the treatment of diphtheria?What is involved in the inpatient care of diphtheria?Which medications may be indicated in the treatment of diphtheria?When is admission to an ICU indicated in the treatment of diphtheria?What group is working towards global immunizations and disease prevention of diphtheria?What diphtheria vaccinations are available?What are the CDC recommendations on diphtheria vaccinations for pregnant patients?How have diphtheria immunization schedules changed for adolescent and adult populations?What are the complications of diphtheria?What is the prognosis of diphtheria?What information should all people have about diphtheria?

Author

Bruce M Lo, MD, MBA, CPE, RDMS, FACEP, FAAEM, FACHE, Chief, Department of Emergency Medicine, Sentara Norfolk General Hospital; Medical Ditector, Sentara Transfer Center; Professor and Assistant Program Director, Core Academic Faculty, Department of Emergency Medicine, Eastern Virginia Medical School

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Barry J Sheridan, DO, Chief Warrior in Transition Services, Brooke Army Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Jeter (Jay) Pritchard Taylor, III, MD, Assistant Professor, Department of Surgery, University of South Carolina School of Medicine; Attending Physician, Clinical Instructor, Compliance Officer, Department of Emergency Medicine, Palmetto Richland Hospital

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Employed contractor - Chief Editor for Medscape.

Additional Contributors

Steven A Conrad, MD, PhD, Chief, Department of Emergency Medicine; Chief, Multidisciplinary Critical Care Service, Professor, Department of Emergency and Internal Medicine, Louisiana State University Health Sciences Center

Disclosure: Nothing to disclose.

Acknowledgements

Allysia M Guy, MD Staff Physician, Department of Emergency Medicine, State University of New York Downstate Medical Center

Disclosure: Nothing to disclose.

Lorenzo Paladino, MD Assistant Professor, Department of Emergency Medicine, SUNY Health Science Center at Brooklyn; Consulting Staff, Assistant Director of Research, Department of Emergency Medicine, Kings County Hospital Center

Lorenzo Paladino, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Author: Elzbieta Pilat, MD Staff Physician, Department of Emergency Medicine, State University of New York Downstate, Kings County Hospital Center

Disclosure: Nothing to disclose.

Mark A Silverberg, MD, MMB, FACEP Assistant Professor, Associate Residency Director, Department of Emergency Medicine, State University of New York Downstate College of Medicine; Consulting Staff, Department of Emergency Medicine, Staten Island University Hospital, Kings County Hospital, University Hospital, State University of New York Downstate Medical Center

Mark A Silverberg, MD, MMB, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Council of Emergency Medicine Residency Directors, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Malini K Singh, MD Staff Physician, Department of Emergency Medicine, Jacobi/Montefiore Medical Center

Disclosure: Nothing to disclose.

References

  1. Chen RT, Broome CV, Weinstein RA. Diphtheria in the United States, 1971-81. Am J Public Health. 1985 Dec. 75(12):1393-7. [View Abstract]
  2. Dass J FP, Deepika V. Implications from predictions of HLA-DRB1 binding peptides in the membrane proteins of Corynebacterium diphtheriae. Bioinformation. 2008. 3(3):111-3. [View Abstract]
  3. Dale DC, ed. 16 Infections Due to Gram-Positive Bacilli. Infectious Diseases: The Clinician's Guide to Diagnosis, Treatment, and Prevention. WebMD Corporation; 2007.
  4. Mattos-Guaraldi AL, Sampaio JL, Santos CS, Pimenta FP, Pereira GA, Pacheco LG, et al. First detection of Corynebacterium ulcerans producing a diphtheria-like toxin in a case of human with pulmonary infection in the Rio de Janeiro metropolitan area, Brazil. Mem Inst Oswaldo Cruz. 2008 Jun. 103(4):396-400. [View Abstract]
  5. Bonmarin I, Guiso N, Le Fleche-Mateos A, Patey O, Patrick AD, Levy-Bruhl D. Diphtheria: a zoonotic disease in France?. Vaccine. 2009 Jun 24. 27(31):4196-200. [View Abstract]
  6. Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018 Apr 27. 67 (2):1-44. [View Abstract]
  7. Harnisch JP, Tronca E, Nolan CM, Turck M, Holmes KK. Diphtheria among alcoholic urban adults. A decade of experience in Seattle. Ann Intern Med. 1989 Jul 1. 111(1):71-82. [View Abstract]
  8. Centers for Disease Control and Prevention. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep. 2009 Apr 17. 58(14):374-5. [View Abstract]
  9. Webb TR, Cross SH, McKie L, Edgar R, Vizor L, Harrison J, et al. Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development. J Cell Sci. 2008 Oct 1. 121:3140-5. [View Abstract]
  10. CDC. Summary of notifiable diseases--United States, 2001. MMWR Morb Mortal Wkly Rep. 2003 May 2. 50(53):i-xxiv, 1-108. [View Abstract]
  11. Mattos-Guaraldi AL, Moreira LO, Damasco PV, Hirata Júnior R. Diphtheria remains a threat to health in the developing world--an overview. Mem Inst Oswaldo Cruz. 2003 Dec. 98(8):987-93. [View Abstract]
  12. Vitek CR, Wharton M. Diphtheria in the former Soviet Union: reemergence of a pandemic disease. Emerg Infect Dis. 1998 Oct-Dec. 4(4):539-50. [View Abstract]
  13. de Benoist AC, White JM, Efstratiou A, et al. Imported cutaneous diphtheria, United Kingdom. Emerg Infect Dis. 2004 Mar. 10(3):511-3. [View Abstract]
  14. Wagner KS, White JM, Lucenko I, Mercer D, Crowcroft NS, Neal S. Diphtheria in the postepidemic period, Europe, 2000-2009. Emerg Infect Dis. 2012 Feb. 18(2):217-25. [View Abstract]
  15. Dallman T, Neal S, Green J, Efstratiou A. Development of an online database for diphtheria molecular epidemiology under the remit of the DIPNET project. Euro Surveill. 2008 May 8. 13(19):[View Abstract]
  16. Patel UV, Patel BH, Bhavsar BS. A Retrospective Study of Diphtheria Cases Rajkot, Gujarat. Indian Journal of Community Medicine. 2004. XXIX, No 4:
  17. Mandell, Bennett, Dolin. Corynebacterium diphtheriae. Principles and Practice of Infectious Diseases. 2005. 2457-2464.
  18. Murphy TV, Slade BA, Broder KR, Kretsinger K, Tiwari T, Joyce PM, et al. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008 May 30. 57:1-51. [View Abstract]
  19. Havaldar PV, Sankpal MN, Doddannavar RP. Diphtheritic myocarditis: clinical and laboratory parameters of prognosis and fatal outcome. Ann Trop Paediatr. 2000 Sep. 20(3):209-15. [View Abstract]
  20. Muttaiyah S, Best EJ, Freeman JT, Taylor SL, Morris AJ, Roberts SA. Corynebacterium diphtheriae endocarditis: a case series and review of the treatment approach. Int J Infect Dis. 2011 Sep. 15(9):e584-8. [View Abstract]
  21. Holmes RK. Diphtheria, other corynebacterial infections and Anthrax. Principles of Internal Medicine. 2001. 1:909-912.
  22. Dittmann S, Wharton M, Vitek C, et al. Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: lessons learned. J Infect Dis. 2000 Feb. 181 Suppl 1:S10-22. [View Abstract]
  23. Lakkireddy DR, Kondur AK, Chediak EJ. Cardiac troponin I release in non-ischemic reversible myocardial injury from acute diphtheric myocarditis. Int J Cardiol. 2005 Feb 15. 98(2):351-4. [View Abstract]
  24. Lumio JT, Groundstroem KW, Melnick OB, Huhtala H, Rakhmanova AG. Electrocardiographic abnormalities in patients with diphtheria: a prospective study. Am J Med. 2004 Jan 15. 116(2):78-83. [View Abstract]
  25. Centers for Disease Control and Prevention. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR Morb Mortal Wkly Rep. 2008 Oct 3. 57(39):1078-9. [View Abstract]
  26. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage among children aged 19-35 months--United States, 2004. MMWR Morb Mortal Wkly Rep. 2005 Jul 29. 54(29):717-21. [View Abstract]
  27. Centers for Disease Control and Prevention. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR Morb Mortal Wkly Rep. 2008 Oct 10. 57(40):1100-3. [View Abstract]
  28. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2012 Jun 29. 61(25):468-70. [View Abstract]
  29. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged MMWR Morb Mortal Wkly Rep</i>. 2011 Oct 21. 60(41):1424-6. [View Abstract]
  30. Center for Disease Control and Prevention. CDC Advisory Committee for Immunization Practices Recommends Tdap Immunization for Pregnant Women. Available at http://www.cdc.gov/media/releases/2012/a1024_Tdap_immunization.html. Accessed: November 19, 2012.
  31. Dajani NA, Scheifele D. How long can we expect pertussis protection to last after the adolescent booster dose of tetanus-diphtheria-pertussis (Tdap) vaccines?. Paediatr Child Health. 2007 Dec. 12(10):873-4. [View Abstract]
  32. Bronson-Lowe D, Anderson SM. Effects of a minimum interval immunization schedule for diphtheria and tetanus toxoids and acellular pertussis vaccination during a pertussis outbreak. Arch Pediatr Adolesc Med. 2009 May. 163(5):417-21. [View Abstract]
  33. Jayashree M, Shruthi N, Singhi S. Predictors of outcome in patients with diphtheria receiving intensive care. Indian Pediatr. 2006 Feb. 43(2):155-60. [View Abstract]
  34. Lurie P, Stafford H, Tran P. Fatal respiratory diphtheria in a U.S. traveler to Haiti--Pennsylvania, 2003. MMWR Morb Mortal Wkly Rep. 2004 Jan 9. 52(53):1285-6. [View Abstract]
  35. Maksimova NM, Markina SS, Iatskovskii KA, Cherkasova VV, Lazikova GF, Koshkina NA. [Immunization of adult population of Russia against diphtheria in 2006-2007]. Zh Mikrobiol Epidemiol Immunobiol. 2008 Nov-Dec. 27-31. [View Abstract]
  36. Prasad KC, Karthik S, Prasad SC. A comprehensive study on lesions of the pinna. Am J Otolaryngol. 2005 Jan-Feb. 26(1):1-6. [View Abstract]
  37. Zasada AA, Zaleska M, Podlasin RB, Seferynska I. The first case of septicemia due to nontoxigenic Corynebacterium diphtheriae in Poland: case report. Ann Clin Microbiol Antimicrob. 2005 May 5. 4:8. [View Abstract]

Photomicrograph depicts a number of gram-positive Corynebacterium diphtheriae bacteria, which had been stained using the methylene blue technique. The specimen was taken from a Pai's slant culture.

The characteristic thick membrane of diphtheria infection in the posterior pharynx.

Cervical edema and cervical lymphadenopathy from diphtheria infection produce a bull's neck appearance in this child. Source: Public Domain www.immunize.org/images/ca.d/ipcd1861/img0002.htm.

The characteristic thick membrane of diphtheria infection in the posterior pharynx.

Cervical edema and cervical lymphadenopathy from diphtheria infection produce a bull's neck appearance in this child. Source: Public Domain www.immunize.org/images/ca.d/ipcd1861/img0002.htm.

Photomicrograph depicts a number of gram-positive Corynebacterium diphtheriae bacteria, which had been stained using the methylene blue technique. The specimen was taken from a Pai's slant culture.